60 completed, 14 terminated, 6 recruiting, 5 unknown. 29 Not applicable, 23 Phase 4, 13 Phase 3, 6 Phase 2, 4 Phase 1.
Follow Fresenius Kabi: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The FORCE Trial Pilot: Fish Oil-enriched Nutrition for Radiotherapy in Cancer of the hEad and Neck Nutrition counseling, Fresubin Supportan - Head &Amp;Amp; Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Anna Arthur, PhD | 15 | 2027-06-01 | 2026-08-07 |
| Intravenous Fish Oil Emulsion in Critically Ill Patients With High Inflammatory Status. Omegaven (10% fish-oil emulsion; Fresenius-Kabi) - Critical Illness | Phase 2 | Recruiting | Lee Zheng Yii | 159 | 2026-07-07 | 2026-10-20 |
| Glycaemic Index Measurement of an Oral Nutritional Supplement With Biomarker Assessment and Lifestyle Monitoring in Healthy Participants ONS, glucose - Healthy Participants | Not applicable | Not yet recruiting | Fresenius Kabi | 30 | 2026-03-01 | 2026-03-23 |
| Plant-based Versus Animal-based Oral Nutritional Supplements Fresubin Plant-based drink vanilla©, Fresubin Yodrink raspberry© - Risk of Malnutrition | Not applicable | Recruiting | Radboud University Medical Center | 60 | 2025-11-10 | 2026-08-11 |
| Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment Omegaven® (fish oil triglycerides) Injectable Emulsion - Parenteral Nutrition Associated Liver Disease (PNALD), Essential Fatty Acid Deficiency | Recruiting | Fresenius Kabi | 40 | 2024-12-15 | 2026-08-14 | |
| Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients SMOFlipid® (lipid injectable emulsion) - Malnutrition, Child, Malnutrition | Phase 4 | Recruiting | Fresenius Kabi | 100 | 2024-10-28 | 2026-10-22 |
| Achieving nuTritional Target in criticAlly Ill patieNts With iMpairEd gastroiNtesTinal Dysfunction Supplemental Parenteral Nutrition (SPN) - Parenteral Nutrition, Gastroparesis | Not applicable | Recruiting | Romanian Society for Enteral and Parenteral Nutrition | 164 | 2024-10-01 | 2024-11-06 |
| Improved Muscle Metabolism by Combination of Muscle Activation and Protein Substitution ( IMEMPRO ) Dietary Supplement: additional substitution of protein, Neuromuscular electrical stimulation, Early Mobilization - ICU Acquired Weakness, Muscle Atrophy | Not applicable | Recruiting | Technical University of Munich | 40 | 2023-06-27 | 2026-03-03 |
| Accelerated Recovery Following Opioid-free Anaesthesia in Supratentorial Craniotomy Lignocaine, Dexmedetomidine, Sevoflurane, Paracetamol, Parecoxib - Opioid-Free Anaesthesia | Not applicable | Completed | University of Malaya | 25 | 2023-01-01 | 2024-04-09 |
| Absorption of Antibiotics With High Oral Bioavailability in Short-bowel Syndrome Amoxicillin, Levofloxacin, Ofloxacin - Short Bowel Syndrome, Infection, Bacterial | Phase 1 | Unknown | Central Hospital, Nancy, France | 10 | 2022-12-09 | 2024-08-29 |
| bIosimilar of aDalimumab, an European evAluation Rheumatoid Arthritis, Ankylosing Spondylitis | Unknown | Fresenius Kabi | 1050 | 2022-04-30 | 2022-01-13 | |
| Investigating the Digestibility, Bioavailability and Utilisation of Varied Combined Protein Sources in Older Males Using a Dual Stable Isotope Tracer Technique Randomised 20g Protein Supplement - Healthy Male Volunteers Over 65 | Not applicable | Completed | University of Nottingham | 32 | 2022-04-25 | 2025-06-26 |
| Safety of Omegaven in Pediatric Patients With Parenteral Nutrition-Associated Cholestasis (PNAC) Omegaven® (fish oil triglycerides) Injectable Emulsion - Parenteral Nutrition Associated Liver Disease, Essential Fatty Acid Deficiency | Withdrawn | Fresenius Kabi | 2022-04-01 | 2022-08-04 | ||
| Efficacy and Safety of SmofKabiven Extra Nitrogen for Parenteral Nutrition in Patients Receiving Intensive Care SmofKabiven extra Nitrogen - Nutrition Therapy, Critical Illness | Phase 3 | Completed | Fresenius Kabi | 56 | 2022-02-12 | 2024-02-21 |
| umBilical Or Adult Donor Red Blood Cells in Extremely Low Gestational Age Neonates and Retinopathy of Prematurity (BORN) cord blood-RBC concentrates, adult donor RBC concentrates - Retinopathy of Prematurity | Phase 2 | Completed | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 146 | 2021-12-01 | 2025-02-27 |
| Effect of Combined IV Bolus Amino Acid Supplementation and Mobilisation on Skeletal Muscle During the First 10 Days in the ICU: A RCT Combined cycle ergometry and bolus amino acid supplementation - Critical Illness | Not applicable | Completed | University of Stellenbosch | 50 | 2021-05-24 | 2025-12-03 |
| Effect of a Hyperproteic Hyperenergetic Enteral Formula on Body Composition and VEGF in AML During Hospital Stay Experimental group, Control group - Acute Myeloid Leukemia, Adult | Not applicable | Unknown | Hospital General de Mexico | 74 | 2020-12-01 | 2020-09-03 |
| Oral Nutritional Supplement for the Patient With or at Risk of Malnutrition Fresubin® powder fibre - Malnutrition | Not applicable | Completed | Chinese University of Hong Kong | 88 | 2020-11-15 | 2022-10-07 |
| A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response Crohn Disease, Ulcerative Colitis | Completed | Fresenius Kabi | 754 | 2020-09-29 | 2023-07-19 | |
| Safety and Efficacy Study to Compare Smoflipid and Intralipid 20% in Pediatric Patients of 3 Months to 16 Years of Age Smoflipid, Intralipid, 20% - Malnutrition, Child | Phase 4 | Terminated | Fresenius Kabi | 1 | 2019-12-18 | 2022-12-12 |
Showing 20 of 89. Sign in to see all of them.
Hyperphagia (13) · Malnutrition (13) · Critical Illness (10) · Renal Insufficiency, Chronic (7) · Acute Kidney Injury (4) · Neoplasms (4) · Diabetes Mellitus (3) · Sepsis (3) · Arthritis, Psoriatic (2) · Arthritis, Rheumatoid (2) · Cachexia (2) · Child Nutrition Disorders (2) · Colitis, Ulcerative (2) · Crohn Disease (2) · Diabetes Mellitus, Type 2 (2)
Hydroxyethyl Starch Derivatives (10) · Food (8) · HES 130-0.4 (7) · Dietary Supplements (5) · fish oil triglycerides (5) · Sodium Chloride (4) · soybean oil, phospholipid emulsion (4) · Glucose (3) · SMOFlipid (3) · Serum Albumin, Human (3) · Solutions (3) · alanylglutamine (3) · ketosteril (3) · Acetaminophen (2) · Glutamine (2)
Germany (23) · France (13) · Austria (8) · United States (8) · Netherlands (7) · Canada (6) · China (6) · Poland (6) · Belgium (5) · Italy (5) · United Kingdom (5) · Czechia (4) · Spain (4) · Switzerland (4) · Australia (3)
Cornelius Koch, MD (2) · Jeffrey Rudolph, MD (2) · John F Stover, M.D. (2) · John F Stover, MD (2) · Wolfgang F. Buhre, Prof. Dr. med. (2) · Aleksander Y. Zemchenkov, MD (1) · Alexander Zarbock, MD, PhD (1) · Anders Perner, Professor, MD, PhD (1) · Andra Duncan, M.D. (1) · Andrea Schneider, Dr. med. (1) · Bala Venkatesh (1) · Bart de Keulenaer (1) · Benno Ihle (1) · Bertrand Guidet, Prof., MD (1)
PMID 30017128, PMID 1015603, PMID 11331167, PMID 11331334, PMID 11374619, PMID 11448575, PMID 11472277, PMID 12411815, PMID 12548273, PMID 12560416, PMID 12765673, PMID 14622770, PMID 15530127, PMID 1559306, PMID 17138203, PMID 17413915, PMID 18061312, PMID 18686750, PMID 18687132, PMID 18762870, PMID 19157368, PMID 19174373, PMID 19690943, PMID 20094812, PMID 20622656, PMID 21621886, PMID 22444237, PMID 22506940, PMID 22624531, PMID 2292168, PMID 23075127, PMID 23569691, PMID 23594003, PMID 23731998, PMID 23765693, PMID 23788067, PMID 23878064, PMID 24667978, PMID 24803474, PMID 24970272, PMID 24992948, PMID 25175758, PMID 25301845, PMID 25603226, PMID 2589650, PMID 25927460, PMID 26011204, PMID 26172830, PMID 26330019, PMID 26420176
2016 (2), 2018 (2), 2009 (1), 2017 (1), 2025 (1)